Nova Patents
AT339498T

Modified protein kinase a-specific hybrid oligonucleotide in combination with paclitaxol and methods of their use

Abstract

(57) It supplements with the nucleotide which enciphers the RIa secondary unit of summary A type protein キネーゼ, and the improvement oligonucleotide of the composition which can carry out lower part control indicates expression. The improvement oligonucleotide has 15 to about 30 nucleotides, and is an oligonucleotide of a hybrid, a reversal hybrid, or a reversal chimera. Moreover, the method of using the composition for medical treatment containing such an oligonucleotide and it is also indicated.

Term

No projected expiry on record.

  1. Priority
  2. Filed
  3. Granted
  4. Today

64 members in 11 offices

This recordMember, by publication datePriority claim1 more office is in the list below

Priority claims1

Priority claims
DocumentOfficeKindDate
4074097United States of AmericaP

Members64

Family members, oldest first
DocumentOfficeKind
CA2229811A1CanadaA1
WO9706662A2World Intellectual Property Organization (WIPO)A2
AU6953896AAustraliaA
CA2232724A1CanadaA1
WO9711171A1World Intellectual Property Organization (WIPO)A1
AU7241296AAustraliaA
WO9706662A3World Intellectual Property Organization (WIPO)A3
US5652356AUnited States of AmericaA
EP0846170A1European Patent Office (EPO)A1
US5773601AUnited States of AmericaA
CA2283626A1CanadaA1
WO9840479A1World Intellectual Property Organization (WIPO)A1
AU6328598AAustraliaA
JPH11512088AJapanA
US5969117AUnited States of AmericaA
US5973136AUnited States of AmericaA
JPH11512601AJapanA
EP1007656A1European Patent Office (EPO)A1
EP1019428A2European Patent Office (EPO)A2
CA2390975A1CanadaA1
WO0134093A2World Intellectual Property Organization (WIPO)A2
AU1474901AAustraliaA
EP0846170B1European Patent Office (EPO)B1
AT203271TAustriaT
ATE203271T1AustriaT1
DE69613984D1GermanyD1
WO0134093A3World Intellectual Property Organization (WIPO)A3
DE69613984T2GermanyT2
JP2002501370AJapanA
EP1229938A2European Patent Office (EPO)A2
JP2003513894AJapanA
US2003105035A1United States of AmericaA1
EP1019428B1European Patent Office (EPO)B1
AT243706TAustriaT
ATE243706T1AustriaT1
DE69628864D1GermanyD1
EP1340765A2European Patent Office (EPO)A2
DK1019428T3DenmarkT3
US6624293B1United States of AmericaB1
PT1019428EPortugalE
ES2201198T3SpainT3
DE69628864T2GermanyT2
US2004106570A1United States of AmericaA1
US2005054600A1United States of AmericaA1
WO2005115480A2World Intellectual Property Organization (WIPO)A2
EP1340765A3European Patent Office (EPO)A3
WO2005115480A3World Intellectual Property Organization (WIPO)A3
US7074768B2United States of AmericaB2
EP1007656B1European Patent Office (EPO)B1
EP1229938B1European Patent Office (EPO)B1
AT339212TAustriaT
AT339498TThis recordAustriaT
ATE339212T1AustriaT1
ATE339498T1AustriaT1
DE60030754D1GermanyD1
DE69835886D1GermanyD1
DE60030754T2GermanyT2
AT411333TAustriaT
ATE411333T1AustriaT1
EP1340765B1European Patent Office (EPO)B1
JP4177455B2JapanB2
DE69637718D1GermanyD1
ES2315442T3SpainT3
CA2229811CCanadaC